MYH9 and neoplasm: Additionally, blebbistatin treatment inhibited MYH9, resulting in cytoskeleton inhibition, corresponding changes in tumor cell morphology, and disappearance of marginal colocalization of Hsp90, ENO1, and PKM2 in tumor cells (Figure 5J and Figure S4F, Supporting Information).